乳がん患者を対象としたサシツズマブ チルモテカン（Sac-TMT、MK-2870）の臨床試験（MK-2870-032）
基本情報
- NCT ID
- NCT06966700
- ステータス
- 募集中
- 試験のフェーズ
- 第3相
- 試験タイプ
- 介入
- 目標被験者数
- 2,400
- 治験依頼者名
- Merck Sharp & Dohme LLC
概要
Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of breast cancer in this study are triple-negative breast cancer (TNBC) and hormone receptor (HR)-low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. These cancers have zero or a low amount of a protein called HER2 and other proteins that attach to the hormones estrogen or progesterone. Sacituzumab tirumotecan (also known as sac-TMT or MK-2870), the study medicine, is a type of targeted therapy. A targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. The main goals of this study are to learn if people who receive sac-TMT, pembrolizumab, and chemotherapy: * Have fewer cancer cells found in the tumors and lymph nodes removed during surgery compared to those who receive only pembrolizumab and chemotherapy * Live longer without the cancer growing, spreading, or coming back compared to people who receive only pembrolizumab with chemotherapy
対象疾患
介入
依頼者（Sponsor）
実施施設 (30)
独立行政法人国立病院機構大阪医療センター
Osaka, Japan(RECRUITING)
Kyoto University Hospital ( Site 2313)
Kyoto, Japan(RECRUITING)
Kanagawa Cancer Center ( Site 2308)
Yokohama, Kanagawa, Japan(RECRUITING)
くまもと森都総合病院
Kumamoto, Japan(RECRUITING)
国家公務員共済組合連合会 虎の門病院
Minato, Tokyo, Japan(RECRUITING)
Mie University Hospital ( Site 2312)
Tsu, Mie-ken, Japan(RECRUITING)
関西医科大学附属病院
Hirakata, Osaka, Japan(RECRUITING)
Kanazawa Medical University Hospital ( Site 2321)
Kahoku-gun, Ishikawa-ken, Japan(RECRUITING)
近畿大学病院
Sakai, Osaka, Japan(RECRUITING)
Naha Nishi Clinic ( Site 2320)
Naha, Okinawa, Japan(RECRUITING)
国立大学法人 三重大学医学部附属病院
Tsu, Mie-ken, Japan(RECRUITING)
地方独立行政法人広島市立病院機構 広島市立広島市民病院
Hiroshima, Japan(RECRUITING)
地方独立行政法人 大阪府立病院機構 大阪国際がんセンター
Suita, Osaka, Japan(RECRUITING)
Nakagami Hospital ( Site 2323)
Okinawa, Japan(RECRUITING)
京都大学医学部附属病院
Kyoto, Japan(RECRUITING)
Fukushima Medical University Hospital ( Site 2301)
Fukushima, Japan(RECRUITING)
Kansai Medical University Hospital ( Site 2317)
Hirakata, Osaka, Japan(RECRUITING)
公立大学法人 福島県立医科大学附属病院
Fukushima, Japan(RECRUITING)
秋田大学医学部附属病院
Akita, Japan(RECRUITING)
神奈川県立がんセンター
Yokohama, Kanagawa, Japan(RECRUITING)
独立行政法人国立病院機構北海道がんセンター
Sapporo, Hokkaido, Japan(RECRUITING)
National Cancer Center Hospital ( Site 2305)
Chūō, Tokyo, Japan(RECRUITING)
国立研究開発法人国立がん研究センター中央病院
Chūō, Tokyo, Japan(RECRUITING)
地方独立行政法人 静岡市立静岡病院
Sunto-gun, Shizuoka, Japan(RECRUITING)
千葉県がんセンター
Chiba, Japan(RECRUITING)
静岡県立静岡がんセンター
Sunto-gun, Shizuoka, Japan(RECRUITING)
社会医療法人 敬愛会 中頭病院
Okinawa, Japan(RECRUITING)
大阪大学医学部附属病院
Suita, Osaka, Japan(RECRUITING)
昭和医科大学病院
Shinagawa, Tokyo, Japan(RECRUITING)
名古屋市立大学病院
Nagoya, Aichi-ken, Japan(RECRUITING)